Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

摘要: BACKGROUND Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs PS remains unknown. It was hypothesized that Eastern Cooperative Oncology Group (ECOG) (≥2 vs 0-1) would correlate shorter overall survival (OS) in receiving ICIs. METHODS In this retrospective cohort study, clinicopathologic, treatment, outcome data were collected aUC who treated at 18 institutions (2013-2019). The response rate (ORR) OS compared ECOG 0 to 1 PS ≥ 2 ICI initiation. association between new last 30 90 days life (DOL) death location also tested. RESULTS Of 519 ICIs, 395 384 included ORR analyses, respectively, 26% 24% having PS ≥ 2. higher those than first line (median, 15.2 7.2 months; hazard ratio [HR], 0.62; P = .01) but not subsequent lines 9.8 8.2 months; HR, 0.78; P = .27). ORRs similar both lines. 288 died, 10% 32% started 90 DOL, respectively. initiation DOL associated increased odds hospital (odds ratio, 2.89; P = .04). CONCLUSIONS Despite comparable ORRs, may overcome negative prognostic role PS, particularly first-line setting, location.